Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject signed informed consent form (ICF)~* Age 40 and above- Male with symptomatic BPH.~* IPSS symptom severity score ≥ 13~* Peak urinary flow of \< 12 ml/sec~* Prostate volume between 25 ml to 80 ml (assessed by pre-operative ultrasound - TRUS)~* Blood CBC and biochemistry up to two weeks before screening, demonstrating: Normal values of the PT, PTT and INR tests (Anticoagulants washout may be done two weeks prior of device implantation)~* Subject able to comply with the study protocol~* Normal urinalysis and negative urine culture~* Subjects that are able to undergo MRI.~Exclusion Criteria:~* A post void residual (PVR) volume \> 250 ml measured by ultrasound or acute urinary retention~* Confirmed or suspected bladder cancer;~* Recent (within 3 months) cystolithiasis or hematuria;~* Urethral strictures, bladder neck contracture, urinary bladder stones or other potentially confounding bladder pathology;~* An active urinary tract infection.~* Enrolled in another treatment trial for any disease within the past 30 days.~* Previous colo- rectal surgery (other than hemorrhoidectomy) or history of rectal disease if the therapy may potentially cause injury to sites of previous rectal surgery, e.g., if a transrectal probe is used;~* Previous pelvic irradiation, cryosurgery or radical pelvic surgery;~* Previous prostate surgery, balloon dilatation, stent implantation, laser prostatectomy, hyperthermia, or any other invasive treatment to the prostate~* Median lobe obstruction of the prostate (larger than 1cm).~* Cancer that is not considered cured, except basal cell or squamous cell carcinoma of the skin (cured defined as no evidence of cancer within the past 5 years)~* Patient with renal dysfunction~* Any serious medical condition likely to impede successful completion of the study

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iTind arm (Type: EXPERIMENTAL): ITind device implant

Based on this trial design, predict the completion outcome and termination type (if applicable).